P-MUC1C-ALLO1 is under clinical development by Poseida Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how P-MUC1C-ALLO1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
P-MUC1C-ALLO1 overview
P-MUC1CALLO-1 is under development for the treatment of solid tumors derived from epithelial cells tumors including triple-negative breast cancer, renal cancer, ovarian cancer, non-small cell lung cancer, esophageal cancer, gastric cancer, pancreatic cancer and colorectal cancers. The drug candidate is administered through intravenous route. It comprises of allogeneic stem memory T cells (Tscm), genetically engineered to express chimeric antigen receptor (CAR). It acts by targeting the cells expressing mucin1. The therapeutic candidate is being developed based on Piggybac DNA modification system and CAS Clover gene-editing technology.
Poseida Therapeutics overview
Poseida Therapeutics is a biopharmaceutical company. It utilizes proprietary gene engineering platform, to develop cell and gene therapies to treat solid tumors and hematological malignancies. The company’s product pipeline include P-PSMA-ALL01 for treatmane of solid tumors; and other drug programs such as P-BCMA-ALL01, P-BCMACD19-ALL01, P-CD19CD20-ALL01, and P-CD70=ALL01 to treat heme malignancies. Poseida Therapeutics is also investigating P-OTC-101, P-FVIII-101, and P-PAH-101 programs for liver diseases. The company works in collaboration with Roche. Poseida Therapeutics is headquartered in San Diego, California, the US.
For a complete picture of P-MUC1C-ALLO1’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
